| Wed 22 Sep 2010, 12:05 | | CMP - CIPLA MEDPRO SOUTH AFRICA LIMITED - Official commissioning of the new |
|
CMP
CMP
CMP - CIPLA MEDPRO SOUTH AFRICA LIMITED - Official commissioning of the new
R329m manufacturing facility for Cipla Medpro in Durban
CIPLA MEDPRO SOUTH AFRICA LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2002/018027/06)
(ISIN Number: ZAE000128179 Share Code: CMP)
Official commissioning of the new R329m manufacturing facility for Cipla Medpro
in Durban
The Honourable President of the Republic of South Africa, Jacob Zuma, will today
open a new R329m state-of-the-art pharmaceutical manufacturing facility in
Durban, KwaZulu Natal, owned by JSE-listed Cipla Medpro South Africa (CMSA).
Cipla Medpro Manufacturing (CMM), part of the JSE-listed CMSA Limited, houses
the company`s Durban-based MCC-approved manufacturing facility - one of the
largest pharmaceutical manufacturing plants of its kind in South Africa.
CMSA Limited, which recently invested R329m in upgrading the plant to
international Pharmaceutical Inspection Co-operation Scheme (PIC/s) standards,
offers high volume contract manufacturing solutions in line with cGMP and PIC/s
standards to both large local and multinational pharmaceutical companies,
including select lines of the group`s own products.
The facility is also one of only two plants in South Africa offering
manufacturing capability for effervescent formulations.
In recognition of the important role played by education in the development of
the country, Cipla Medpro (Pty) Ltd will, simultaneously with the commissioning
of its new manufacturing plant, make a R1,5m donation to the Jacob Zuma RDP
Educational Trust.
In accordance with the wishes of Cipla Medpro, the educational grant will be
used primarily in the field of post-matric studies in engineering, medicine and
pharmaceutical studies.
Says S`bu Luthuli, Chairman of Cipla Medpro South Africa Ltd:
"We are making this donation to the Jacob Zuma RDP Educational Trust in
acknowledgement of the important role that tertiary technical education in the
fields of science, medicine and engineering plays in the development of our
country.
"A core principal of Cipla Medpro South Africa Limited is a belief that
affordable healthcare is a right for all South Africans, not a privilege. To
this end, we are firmly committed to providing world class, yet affordable
medicines to all."
CMSA has a long-standing relationship with Cipla India, the largest stand alone
generic company in the world and number one pharmaceutical company in India by
value, which enables it access to Cipla India`s impressive pipeline of products.
The company is busy finalising a new transaction in terms of which Cipla India
will eventually acquire a 25% stake in Cipla Medpro Manufacturing.
Once the transaction has been concluded, Cipla India will be in the position to
place additional volumes with CMM`s manufacturing facility as well as assist the
company in achieving the much sought after United Nations public health arm
`WHO` (World Health Organisation) status and `FDA` (Food and Drug
Administration) manufacturing approvals.
Says Jerome Smith, CEO of Cipla Medpro South Africa Ltd:
"Thanks to our strong alliances we are poised to be a significantly greater
provider of low cost, effective, quality medicines in the growing generics
market, aiding in the effective and ongoing treatment of human ailments.
"Our Durban facility is presently contract manufacturing eight State tender
products for Cipla Medpro, based in Cape Town, including two Antiretrovirals,
Efavirenz and Lamivudine. And the factory will also manufacture the ARVs,
Nevirapine and Tenofovir."
"We believe that a positive outcome on Government`s ARV tender will allow us to
take advantage of the abundant capacity of our plant, as well as empowering
Cipla Medpro with the potential opportunity for job creation and the expansion
of our 341-strong diverse work force based at the factory."
Durban
22 September 2010
Sponsor
Nedbank Capital
Date: 22/09/2010 12:05:01 Produced by the JSE SENS Department.
The SENS service is an information dissemination service administered by the
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or
implicitly, represent, warrant or in any way guarantee the truth, accuracy or
completeness of the information published on SENS. The JSE, their officers,
employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature,
howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
